![Memorial Sloan Kettering pediatric oncologist Andrew Harris](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/233689/3x2/harris-andrew_210827_001-1200x800-1.jpg?h=10d202d3)
Andrew Harris, MD
Pediatric Hematologist-Oncologist & Bone Marrow Transplant Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Graft vs Host Disease (GVHD), Pediatric Leukemia, Pediatric Lymphoma
Request an Appointment
About Me
- Associate Attending Pediatrician
I am a physician on the MSK Kids team who specializes in the use of stem cell transplantation and cellular therapies to treat children and adolescents. My patient care expertise and research focus is acute leukemia as well as graft-versus-host disease (GVHD), a potential complication of transplantation that happens when the immune system that is transferred from the donor to the transplant recipient attacks tissues in the recipient’s body.
Read more
I am involved in the leadership of several clinical trials for pediatric acute leukemia and acute and chronic GVHD that are being performed through the Children’s Oncology Group (COG), Blood and Marrow Transplant Clinical Trials Network (BMT CTN), and Pediatric Transplant and Cellular Therapies Consortium (PTCTC). I am leading the MSK Kids multidisciplinary pediatric GVHD clinic that is held at the David H. Koch Center for Cancer Care. I am also the clinical lead for an international clinical study that aims to identify new blood tests to help with the prediction and management of chronic GVHD, which typically occurs later (two months or beyond) after transplant.
I know stem cell transplantation can be a scary and intimidating therapy for families, and I always take the time needed for each patient and family to understand how and why transplantation works, what the risks are, and how our team works together with families to achieve the best possible outcomes for their children. I try to engage each child and get to know the family personally, since our team will be with them for every step of their transplant journey. I value their trust and enjoy developing relationships with them.
I, myself, had a stem cell transplant for high-risk acute myeloid leukemia. I experienced acute GVHD that did not respond to steroid therapy and promised my doctors that I would return to the field to help improve the safety and effectiveness of our treatments. The most gratifying part of my job is having a child get back to their normal activities and seeing the joy this brings them and their families after going through a transplant.
I am the proud father of three incredible teenagers. My wife is an author who writes novels, including new novels for Marvel’s X-Men and Avengers. I am also an avid soccer fan and very much enjoy the outdoors.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
A bone marrow transplant specialist is a doctor with special training in bone marrow transplants.
My Specialties
- Graft vs Host Disease (GVHD), Pediatric Leukemia, Pediatric Lymphoma
Education
- MD, Case Western Reserve University School of Medicine
Residencies
- Pediatrics, Cleveland Clinic
Fellowships
- Pediatric Hematology-Oncology, University of Michigan
Board Certifications
- General Pediatrics
- Pediatric Hematology-Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Harris sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Harris
- A Phase 3 Study of Itolizumab plus Corticosteroids to Treat Acute Graft-Versus-Host Disease
- Clinical Trials Co-Investigated by Dr. Harris
- A Phase 1 Study of Uproleselan Plus Conditioning Chemotherapy and Stem Cell Transplantation in People With Very High-Risk Acute Myeloid Leukemia
- A Phase I/II Study of SMART101 in Children and Adults with Acute Leukemia Who Receive a T-Cell Depleted Stem Cell Transplant from a Donor
- A Phase II Study of Photobiomodulation Therapy in Children and Adults with Oral Graft-versus-Host Disease after Stem Cell Transplantation
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrew Harris discloses the following relationships and financial interests:
-
Center for Personalized Education for Professionals (CPEP)
Professional Services and Activities -
Horizon Pharma PLC
Professional Services and Activities -
Incyte
Professional Services and Activities -
Janssen Scientific Affairs, LLC
Professional Services and Activities
-
Sanofi S.A.
Professional Services and Activities -
Sanofi US Services Inc.
Professional Services and Activities -
Y-mAbs Therapeutics, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].